Active investments
The active medtech book — currently one held position, alongside the realised and historical engagements recorded below. One or two new investments a year. The passive book sits on its own page.
Currently held under the Allure mandate
Seed investor · former Chief Technology Officer
Clinical-grade digital goniometer for joint range-of-motion measurement. Held since the seed round; Nathan also served as Chief Technology Officer at the company. Seed shareholding retained.
CTO
Former role, since concluded
Seed
Entry round
Engagements that have completed · not all were Allure Capital positions
Director (private company) 2014–17 · Executive Director (ASX-listed) 2016–17
Director of the private company from April 2014; led the reverse takeover and December 2015 ASX listing; Executive Director of the listed entity from February 2016 to July 2017. Position fully divested.
2015
RTO listing
ASX:ALC
Ticker
Major shareholder & Executive Vice President, Azure Healthcare · 2012–14
Azure Healthcare (ASX:AZV), since renamed Austco Healthcare (ASX:AHC). Share price moved from 3.3¢ to 34¢ — a roughly 10× return. Position divested. One of Allure's strongest realised engagements.
~10×
Share price, 3.3¢ to 34¢
ASX:AZV
Ticker at exit
Founder, CEO & Chief Technologist · 1992–2010
The originating engagement — before Allure was a firm, this was the principal's operating company. Founded 1992 in a Mosman Park shed and grown to offices across Sydney, Jacksonville, Boca Raton, London, Denmark, China and Hong Kong. Awarded a US Secret Service contract for a mobile emergency-distress platform for the US president. Sold to Amcom Software in October 2008; Amcom's US operation was acquired by USA Mobility (now Spok) for US$163.3m in 2011. The capital from the 2008 trade sale funded the founding of Allure in 2011.
US$163.3m
Amcom US operation to USA Mobility / Spok · 2011
53
Countries deployed
Advisory Board · 2017–22 · sale on behalf of shareholders
Invited back to the firm where the principal had started as a seventeen-year-old software engineer. Joined the advisory board with a brief to find the shareholders an exit, and led the sale of the business on their behalf. Omnitronics was divested to Software Combined in July 2022; the advisory role concluded at the same time.
2022
Sale to Software Combined
5yrs
Advisory board tenure
Non-Executive Director · ASX:RAP · December 2017 – March 2020
Machine-learning diagnostics for respiratory disease, spun out of the University of Queensland. A board seat rather than an Allure holding — no shares were held at resignation. Pfizer (NYSE:PFE) acquired the company by scheme of arrangement on 26 September 2022, thirty months after the tenure ended.
ASX:RAP
Ticker · acquired by Pfizer 2022
NED
Board seat, no shareholding
Engaged for judgement, not capital
A separate strand of work: engagements where the principal was retained for operating judgement rather than an investment. No capital deployed, no shareholding taken — the brief in each case was to help someone else’s shareholders get where they were trying to go. The Omnitronics advisory board and the Azure Healthcare management-consulting role above belong to the same pattern.
Management Consultant · 2011–12
A Perth-based manufacturer of nurse-call systems for the aged-care and acute-care markets. Retained to review the commercial side of the business — branding, marketing, sales and research and development — and to set out a growth strategy for domestic and New Zealand market share. Also prepared the company’s Commercialisation Australia application. The work drew directly on having taken CommtechWireless through the same growth ceiling in the same category.
2011
Strategic review delivered
Nurse call
Aged care & acute care
Consulting & advisory · concluded 2015
Clinical communications and nurse-call technology. An advisory engagement undertaken with the knowledge and consent of the company’s owner, concluding in 2015.
2015
Engagement concluded
Advisory
No shareholding
Want to be the next one
